Tirzepatide Injection
Compounded tirzepatide with additives
A once-weekly GIP and GLP-1 injection for weight loss, compounded with an added ingredient.
About Tirzepatide Injection
Tirzepatide is the active ingredient in Mounjaro and Zepbound. It acts on two gut-hormone receptors, GIP and GLP-1. In the SURMOUNT-1 trial, people taking the highest dose lost about 21% of body weight over 72 weeks. Compounded versions are made by a licensed pharmacy, usually with an added ingredient.
Read the full Tirzepatide guide: research, safety and sources →
How it works
- Complete a short online visit. Answer health questions on our telehealth partner's secure site. Some treatments need lab work first.
- A licensed provider reviews it. They decide whether Tirzepatide Injection is safe and appropriate for you and may message you with questions.
- If prescribed, it ships to you from a licensed U.S. pharmacy, with ongoing check-ins and refills through your provider.
Important safety information
Carries a boxed warning: in rodents it caused thyroid C-cell tumors. Do not use if you or a family member has had medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Nausea, vomiting, diarrhea and constipation are common. Pancreatitis, gallbladder problems, kidney problems and low blood sugar (with other diabetes medicines) can occur. Not for use during pregnancy. Compounded versions are not FDA approved, and FDA does not review them for safety, effectiveness or quality.
This is not a complete list. Your provider will review your health history, medicines and allergies before prescribing, and the pharmacy includes the full prescribing information.